Zobrazeno 1 - 10
of 206
pro vyhledávání: '"new oral anticoagulant"'
Autor:
Danial Amoey, Mohamed Samy, Karim Elbasha, Ahmad Alali, Martin Landt, Arief Kurniadi, Holger Nef, Ralph Tölg, Gert Richardt, Nader Mankerious
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 4, Pp 761-773 (2024)
Abstract Introduction Direct oral anticoagulant (DOAC) dose adjustment is based on age, renal function, and body weight. There is a paucity of data describing the factors associated with the prescription of inappropriate dosage and their impact on cl
Externí odkaz:
https://doaj.org/article/dc08849091fe410ca5a07813b0654557
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Soukeina Bassam, Sara Mansour, Roula Ajrouche, Hawraa Kisserwan, Maya EL-Hajj, Salam Zein, Zahraa Dirani, Amal Al-Hajje
Publikováno v:
Dr. Sulaiman Al Habib Medical Journal, Vol 4, Iss 2, Pp 77-85 (2022)
Abstract The goal of this study was to identify drug-related problems (DRPs) and the factors involved in the imbalance of new oral anticoagulants (NOACs) and vitamin K antagonists in a Lebanese adult population with cardiovascular diseases. An imbala
Externí odkaz:
https://doaj.org/article/14ffbd3a957f467786ccac00bec51d07
Publikováno v:
Heart Views, Vol 23, Iss 1, Pp 10-15 (2022)
Transcatheter aortic valve replacement (TAVR) is a treatment option for patients with asymptomatic severe aortic stenosis who are candidates for a bioprosthesis across the entire spectrum of risk. TAVR carries a risk for thrombotic and bleeding event
Externí odkaz:
https://doaj.org/article/3787b99021014aabad19cabe168b26bc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Indian College of Cardiology, Vol 11, Iss 3, Pp 93-97 (2021)
Venous and arterial thrombosis and thromboembolism are a leading cause of suffering in elderly population. The prevalence of venous and arterial thrombosis (formation of blood clot) and thromboembolism (breakage of thrombus to travel somewhere in cir
Externí odkaz:
https://doaj.org/article/7be0c014870b411a8af8567413497d85
Publikováno v:
Jichu yixue yu linchuang, Vol 40, Iss 8, Pp 1103-1108 (2020)
Novel oral anticoagulants (NOVACs) as blood coagulation factor inhibitors have exhibited pivotal role in thromboembolic event and ischemic cardiovascular disease. Nevertheless, it's application in chronic kidney disease (CKD) patients of stage 3-5 re
Externí odkaz:
https://doaj.org/article/a45365ba4df94264812735bcf5dbf365
Publikováno v:
Clinical Epidemiology, Vol Volume 11, Pp 911-921 (2019)
Wen-Qin Guo,1 Xie-Hui Chen,1 Xiao-Yuan Tian,1 Lang Li2 1Department of Cardiology, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, People’s Republic of China; 2Department of Cardiology, The First Affiliated Hospital of Guangxi Medical
Externí odkaz:
https://doaj.org/article/da84821fbf1b4213a793b50b48b1e746
Autor:
Ekim Sağlam Gürmen, Adnan Bilge
Publikováno v:
Eurasian Journal of Emergency Medicine, Vol 18, Iss 2, Pp 119-121 (2019)
Dabigatran etexilate is a prodrug with anticoagulant effect through inhibition of thrombin. Although it does not require laboratory monitoring and has minimal food-drug interaction, its disadvantages are bleeding, common GIS-related side effects and
Externí odkaz:
https://doaj.org/article/a9a102045202428a88d5def2e33ae66f
Autor:
S. V. Moiseev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 12, Iss 2, Pp 220-226 (2016)
New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke in patients with non-valvular atrial fibrilla
Externí odkaz:
https://doaj.org/article/0988eb4ae9c14b749246a1d318e4ebf0